Public Policy Resources

Share

Community Letter in Support of the DIVERSE Trials Act (H.R. 5030/S. 2706)

November 17, 2021

ACS CAN and more than 150 organizations representing patients, providers and health equity advocates sent a letter to Congress urging them to pass the Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act into law. The legislation would allow trial sponsors to reimburse patients for non-medical costs associated with their trial participation, such as travel, parking, food, or lodging; allow sponsors to provide patients with technology necessary to facilitate remote participation in clinical trials; and require the Department of Health and Human Services (HHS) to create guidance on the use of decentralized trials to increase trial diversity.

PDF icon Download DIVERSE Trials Act Community Letter

Related Resources

July 18, 2022

Survivor Views: Copay Assistance and Patient Navigation

Prescription drug costs are a significant burden on cancer patients and survivors, sometimes even leading patients to miss or delay taking prescribed medications. The latest Survivor Views survey explores the role copay assistance programs can play in reducing this burden, and also addresses patient navigation and digital therapeutics.

Read More

ACS CAN Comments on Draft FDA Guidance on Clinical Trial Diversity Plans

June 13, 2022

ACS CAN submitted comments to the U.S. Food and Drug Administration (FDA) on the Diversity Plans To Improve Enrollment of Participants From Underrepresented Racial and Ethnic Populations in Clinical Trials Draft Guidance for Industry. 

Read more

The National Breast & Cervical Cancer Early Detection Program

May 20, 2022

For 30 years, the Centers for Disease Control and Prevention’s National Breast and Cervical Cancer Early Detection Program has decreased disparities in breast and cervical cancer deaths.

Read more